Clinical Trial Update: CPX-351 Plus Enasidenib for Relapsed AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating CPX-351 in combination with enasidenib for relapsed/refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)
• Enasidenib (enasidenib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Recurrent Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING